Role of E-cigarettes and Pharmacotherapy During Attempts to Quit Cigarette Smoking: The PATH Study 2
Thursday, October 22, 2020
Posted by: Natalia Gromov
Pierce JP, Benmarhnia T,
Chen R, White M, Abrams DB, Ambrose BK, et al. (2020)
Role of E-cigarettes and
Pharmacotherapy During Attempts to Quit Cigarette Smoking: The PATH Study 2013-
16.
PLoS ONE 15(9): e0237938. https://doi.org/
10.1371/journal.pone.0237938
Among daily smokers with an LQA, 23.5% used e-cigarettes, 19.3% used
pharmacotherapy only (including NRT) and 57.2% used no product. Cigarette
abstinence for 12+ months at W3 was ~10% in each group. Half of the cigarette
abstainers in the e-cigarette group were using e-cigarettes at W3. Different
methods to help quitting had statistically comparable 12+ month cigarette
abstinence at W3 (e-cigarettes vs no product: Risk Difference (RD) = 0.01, 95%
CI: -0.04 to 0.06; e-cigarettes vs pharmacotherapy: RD = 0.02, 95% CI:-0.04 to
0.09). Likewise, daily e-cigarette users at W2 did not show a cessation benefit
over comparable no-e-cigarette users and this finding was robust to sensitivity
analyses. Abstinence for 30+ days at W3 was also similar across products.
|
|
Email to a Friend